ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment - Full Text View

Sponsor:	elbion AG
Information provided by:	elbion AG
ClinicalTrials.gov Identifier:	NCT00322803

Purpose

This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.

Condition	Intervention	Phase
Panic Disorder	Drug: ELB139	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Panic Disorder

U.S. FDA Resources

Further study details as provided by elbion AG:

Primary Outcome Measures:

degree of subjective anxiety as measured on a Visual Analogue Scale for Anxiety(VAS-A) assessed immediately after the CO2-challenge (VAS-A-post)
difference of the degree of anxiety measured as the difference between the pre- and post challenge scores on the Visual Analogue Scale for Anxiety (VAS-A-delta)

Secondary Outcome Measures:

Total Symptom Score assessed immediately after CO2 challenge (TSS-post)
Difference of the Total Symptoms Score (TSS) measured as the difference between the pre- and post challenge scores (TSS-delta)

Estimated Enrollment:	24
Study Start Date:	May 2006
Estimated Study Completion Date:	October 2006

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of concurrent panic disorder
At least 2 panic attacks within the 4 weeks before the screening visit
Naïve to the CO2 challenge test
Age 18–65 years (inclusive)
Ability to comply with all procedures mandated by the study protocol
Negative pregnancy test and adequate contraceptive measures

Exclusion Criteria:

History of poly-pharmacotherapy for panic disorder or treatment resistance
Any current psychiatric Axis I DSM-IV diagnosis other than panic disorder, except concurrent simple phobia
History of abuse of benzodiazepines or tolerance to effects of benzodiazepine
Any concomitant psychotropic medication
Evidence of impaired hepatic, renal or cardiac functions
Participation in any drug trial in the preceding 6 months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00322803

Locations

Germany
Charité – University Clinics Berlin
Berlin, Germany, 10117
Emovis, The institute of emotional health
Berlin, Germany, 10629
Netherlands
Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University
Maastricht, Netherlands, 6200 MD

Sponsors and Collaborators

elbion AG

Investigators

Principal Investigator:

Eric Griez, Prof Dr

Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00322803 History of Changes
Other Study ID Numbers:	ELB139202-05, EudraCT Number:2005-005708-17
Study First Received:	May 5, 2006
Last Updated:	September 27, 2006
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by elbion AG:

panic disorder
proof of concept

Additional relevant MeSH terms:

Panic Disorder
Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on February 09, 2012